ClinicalTrials.gg

Pain clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 10,069 studies for Pain across more than 10 countries. 1,650 are recruiting or about to start. 5,301 of them are mainly about Pain (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 45 narrower conditions too, such as Postoperative Pain: 24,377 studies, 4,599 open.

ClinicalTrials.gov finds 38,446 studies for Pain. How that becomes 10,066 here

This page counts the studies the registry files under Pain, and those it files under no condition that list Painthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 38,446Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −14,068Filed under a narrower condition, counted on its own pageChronic Pain 2,723 · Low Back Pain 2,034 · Neck Pain 945 · Acute Pain 740 · Neuralgia 670 · Headache 617 · 36 more
  3. −6,369List Pain as a condition, but the registry did not file them under itMost often written as “Postoperative Pain” (1,823), “Pain, Postoperative” (1,145), and “Pain Management” (370). The registry filed 185 of them under no condition at all, and the others under other conditions only, most often Pain, Postoperative (4,003) and Agnosia (823).
  4. −7,943Match it another way6,382 name it in the title, 1,193 in a keyword, and 368 by a synonym or other text the search reads.
  5. 10,066The count on this page936 of them list Pain in their own words; the registry filed them under no condition.

Status

Completed
6,395
Recruiting
927
Status unknown
926
Not yet recruiting
597
Terminated
545
Withdrawn
275

Phase

Phase 4
934
Phase 3
878
Phase 2
835
Phase 1
456
Early Phase 1
111

Where

United States
2,882
Turkey
1,720
France
482
Canada
461
Pakistan
352
Spain
341

Who develops what

Add Pain to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 31 programs from 27 companies, 17 with this as their studies’ main aim; 6 with a live phase 3 study; 9 primary completions in the next 12 months. Compare HALEON, Jiangsu HengRui Medicine and Vertex Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
MorphineRecent, repeated
Evidence
  • NCT07551739 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 · live · comparator · “morphine” · registered Apr 2026
  • NCT07533786 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 · live · comparator · “morphine” · registered Apr 2026
  • NCT06901830 · Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 2 · comparator · “Active Comparator: Morphine” · registered Mar 2025
  • NCT06890533 · Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 3 · live · comparator · “Active Comparator: Morphine” · registered Mar 2025
  • NCT06680466 · Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 2 · comparator · “morphine” · registered Nov 2024
Teva Pharmaceutical Industries, Ltd.20% of its industry studiesUS: off-patent, 20 generics marketed36 studies
TramadolRecent, repeated
Evidence
  • NCT06237231 · EMS · Phase 3 · live · comparator · “TRAMADOL” · registered Jan 2024
  • NCT06215859 · Viatris Inc. · Phase 3 · comparator · “Tramadol” · registered Dec 2023
  • NCT06215820 · Viatris Inc. · Phase 3 · comparator · “Tramadol” · registered Dec 2023
  • NCT05470075 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “Tramadol hydrochloride SR Tablets” · registered Jul 2022
  • NCT01983111 · Mundipharma · Phase 4 · comparator · “tramadol/acetaminophen” · registered Oct 2013
Johnson & Johnson37% of its industry studiesUS: off-patent, 12 generics marketed34 studies

20 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Triamcinolone AcetonideApproved: US☆ Track1 live phase-3 study: NCT07832552harrow inc
cebranopadol☆ Track1 live phase-3 study: NCT07845071Adneuris Therapeutics, Inc.
susineridine☆ Track1 live phase-3 study: NCT06890533Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

The 3 in phase 3 with the nearest primary completion, of 31 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (9)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.HSK55718 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 main aim+ HSK55718 vs MorphineNCT07551739 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery — primary endpoint: Sum of Pain Intensity Differences (SPID) · 200 enrolled
  • Nov 2026 est.KBP-336 · KeyBioscience AG · Phase 2 registry mapping onlyNCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis — primary endpoint: The proportional change in body weight from baseline to endpoint · 600 enrolled
  • 22 Nov 2026 est.HSK55718 · Haisco Pharmaceutical Group Co., Ltd. · Phase 2 main aim+ HSK55718 vs MorphineNCT07533786 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery — primary endpoint: Sum of Pain Intensity Differences (SPID) · 200 enrolled

6 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pain studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 25 open · Opioids 15 open · Corticosteroids 15 open · NSAIDs 14 open · SNRIs 4 open

Coming up

559studies finish main data collection within a year19 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger. 146 (16%) take children under 18. 123 (13%) are for women only and 11 (1%) for men only; 221 (24%) take healthy volunteers.

Recruiting studies that take each age, of 927
AgeWomenMen
1086 (9%)82 (9%)
18673 (73%)586 (63%)
30747 (81%)642 (69%)
40749 (81%)653 (70%)
50709 (76%)634 (68%)
65643 (69%)581 (63%)
75518 (56%)471 (51%)
85439 (47%)395 (43%)

Across all 10,069 studies, recruiting or not: 51% stop at 75 or younger and 42% at 65; 17% take children; 14% are for women only and 3% for men only; 29% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pain studies take

Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 19 mo3–29 · 220 studies4 mo1–9 · 104 studies23 mo9–45 · 116 studies
Phase 1/211 mo7–36 · 34 studies——
Phase 221 mo7–40 · 186 studies8 mo5–19 · 62 studies33 mo13–60 · 124 studies
Phase 2/320 mo13–30 · 41 studies—21 mo13–51 · 35 studies
Phase 318 mo9–38 · 216 studies13 mo8–23 · 105 studies30 mo14–50 · 111 studies
Phase 418 mo8–33 · 295 studies—18 mo10–35 · 280 studies
Interventional, no phase10 mo4–23 · 3,839 studies13 mo5–30 · 99 studies10 mo4–23 · 3,740 studies
Observational18 mo8–41 · 519 studies—19 mo8–42 · 504 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting17

Show 12 more

Newly registered66

Show 45 more

and 16 more not listed

Studies

Recruiting first, then most recently updated. Showing 50 of 10,069. Browse all 10,069 → or search them.